SP-6300

SP-6300 is an investigational small molecule cortisol modulator developed by Samaritan Pharmaceuticals for the treatment of Cushing's syndrome (hypercortisolism). The drug's mechanism of action involves the reduction of mRNA levels for 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase, the rate-limiting enzyme in the cholesterol biosynthetic pathway. Because cholesterol serves as the essential precursor for corticosteroid synthesis, the reduction in HMG-CoA reductase activity leads to a decrease in the production of cortisol. SP-6300 was designed to provide a targeted approach to managing pathologically elevated cortisol levels. In 2007, the FDA cleared SP-6300 for Phase II clinical trials following successful proof-of-concept studies demonstrating its efficacy as a cortisol modulator.